Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH4336 in Advanced Solid Tumors
NCT05905614Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Nov 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SPH4336 in solid tumor (advanced stage), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Maximum Tolerated Dose up to 28 days and Dose-Limiting Toxicity up to 28 days. Started Nov 2020; status: completed.
02
Drugs
SPH4336
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05905614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905614.